FCGR3A and hematologic disorder: Other clinical studies have been performed, or are ongoing analyzing, the effect of CD19/CD16 [15,40,224,226,229], CD123/CD3 [15], and CD20 × CD16 [231] in hematological malignancies [220,232,233,234,235,236].